Levo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.levotx.com
Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
Phase 3
Completed
- Conditions
- Prader-Willi Syndrome
- Interventions
- Drug: placeboDrug: 3.2 mg intranasal carbetocinDrug: 9.6 mg intranasal carbetocin
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Levo Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03649477
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸University of Harvard Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Vanderbilt University School of Medicine, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath